Configure at GeneGlobe
Find or custom design the right target-specific assays and panels to research your biological targets of interest.
miRCURY LNA miRNA Power Target Site Blockers (5 nmol)
Cat. No. / ID: 339194
5 nmol miRCURY LNA miRNA Power Target Site Blockers with option of different labels and purifications, provided in tube format
Configure at GeneGlobe to see pricing
Type
in vitro
in vivo Ready
In vivo Large Scale
Les miRCURY LNA miRNA Power Target Site Blockers sont destinés aux applications de biologie moléculaire. Ces produits ne sont pas conçus pour le diagnostic, la prévention ou le traitement des maladies.
Configure at GeneGlobe
Find or custom design the right target-specific assays and panels to research your biological targets of interest.
Features
- Custom-designed target site blockers for specific inhibition of miRNA targets
- Sophisticated design and superior high affinity, regardless of target sequence
- Unmatched high efficacy in vitro and in vivo
- Unrivaled performance and high protein expression due to lack of RNase H-dependent mRNA degradation
- Efficient at very low concentrations, outcompeting miRNAs for their target sites
- Superior biological stability for long-lasting antisense activity
Product Details
miRCURY LNA miRNA Power Target Site Blockers are antisense oligonucleotides that bind to the miRNA target site of an mRNA, preventing miRNAs from gaining access to that site. This enables you to study the effects of an miRNA on a single target. miRCURY LNA miRNA Power Target Site Blockers are efficient at very low concentrations, and due to their high affinity from LNA enhancement, the target site blockers outcompete miRNAs for their target sites.
Need a quote for your research project or would you like to discuss your project with our specialist team? Just contact us!
Performance
Unravel miRNA function with target site blockers
miRNAs typically regulate gene expression of multiple targets, and inhibition of an miRNA will result in derepression of all of these targets. Therefore, a phenotype observed upon miRNA inhibition is a composite result of derepression of several targets (see figure miRNA Inhibitors vs. target site blockers). However, deregulation of a few of these targets will often contribute significantly to the phenotype. Identifying these targets is important to understanding the function of the miRNA.miRCURY LNA miRNA Power Target Site Blockers can be used to:
- Determine which pathway is involved in a phenotype observed upon miRNA inhibition
- Determine which miRNA/mRNA interactions are most important in a pathway containing several predicted targets
Examples of target site blocker applications are described in figures Examples of target site blocker applications – pathways X and Y and Examples of target site blocker applications – pathway Z.
The figure The CAV1 target site blocker phenocopies the miR-199a-5p inhibitor in many important aspects shows an example of using a target site blocker to demonstrate how miR-199a-5p functions as a key effector of TGFβ signaling in lung fibroblasts.
See figures
Principle
What are target site blockers?
miRCURY LNA miRNA Target Site Blockers are LNA-enhanced antisense oligonucleotides that bind to the miRNA target site of an mRNA, thereby preventing miRNAs from gaining access to that site. This allows researchers to study the effects of an miRNA on a single target. In contrast, the phenotype observed when inhibiting an miRNA reflects the combined effects of that miRNA on all targets.LNA-enhanced target site blockers
The incorporation of LNA into the miRCURY LNA miRNA Power Target Site Blocker means that they will compete more effectively with the miRNA/RISC complex for the miRNA target site. In addition, LNA distribution throughout the LNA/DNA mixmer ensures that the antisense oligonucleotide does not catalyze RNase H-dependent degradation of the mRNA. As a result, the TSB will cause increased expression of the protein encoded by the targeted mRNA by preventing miRNA-mediated translational attenuation (see figure LNA-enhanced target site blockers compete effectively with RISC for miRNA binding site).See figures
Procedure
Following resuspension, miCURY LNA miRNA Target Site Blockers are transfected into cells with a transfection reagent or via electroporation. Phenotypic effects of the target site blocker are normally assessed 24–72 hours after transfection. For some applications, such as cell differentiation assays, the phenotypic readout may take place 7–10 days after transfection.
Applications
miRCURY LNA miRNA Target Site Blockers can be used for:
- Determining which pathway is involved in a phenotype observed upon miRNA inhibition
- Determining which miRNA/mRNA interactions are most important in a pathway containing several predicted targets
Supporting data and figures
miRNA inhibitors vs. target site blockers.
The phenotype observed when inhibiting an miRNA can be due to many targets being upregulated. Target site blockers (TSB) lead to the upregulation of one specific target and may or may not cause the same phenotype.
Resources
Safety Data Sheets (5)
Scientific Posters (1)
Kit Handbooks (1)
Brochures & Guides (1)